IGF2BP2 and non-small cell lung carcinoma: showed that METTL3 increases m6A levels and expression of transient receptor potential melastatin 7 (TRPM7) mRNA, and enhances the binding of IGF2BP2 and TRPM7, ultimately facilitating angiogenesis in non-small cell lung cancer (NSCLC) (156).